Similar articles

Abstract: To describe the long-term clinical outcomes of patients with autosomal dominant polycystic kidney disease (ADPKD) who are on peritoneal dialysis (PD) therapy. We performed a retrospective matched-cohort analysis comparing the clinical outcomes of 30 ADPKD patients with those of 30 non-diabetic patients who had bilateral small kidneys between July 1 2007 and July 31 2014. The patient groups were matched by age, gender, and time of PD initiation. There were no significant differences in the demographic or biochemical parameters, comorbid conditions, residual glomerular filtration rate, or Charlson comorbidity score at the beginning of PD. The median renal volume was 1315 ml for the ADPKD group and 213 ml for the control group. Patients with ADPKD had similar 3-year patient survival (90.6% versus 86.3%, P=0.807) and technique survival (89.2% versus 74.3%, P=0.506) compared with non-ADPKD patients. Also, there was no significant difference in the peritonitis-free survival between the ADPKD and control groups (P=0.22), and rates of peritonitis were similar (0.19 versus 0.21 episodes per patient-year, P=0.26). No differences were observed in the incidence of PD-related complications, such as hernia and dialysate leak. ADPKD is not a contraindication for PD, and a subgroup of ADPKD patients with relatively small kidney volume can be treated using PD.

多囊肾患者行腹膜透析的预后分析

[1]Bae, K.T., Grantham, J.J., 2010. Imaging for the prognosis of autosomal dominant polycystic kidney disease. Nat. Rev. Nephrol., 6(2):96-106.

[2]Beddhu, S., Bruns, F.J., Saul, M., et al., 2000. A simple comorbidity scale predicts clinical outcomes and costs in dialysis patients. Am. J. Med., 108(8):609-613.

[3]Chapman, A.B., Devuyst, O., Eckardt, K.U., et al., 2015. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int., 88(1):17-27.

[4]del Peso, G., Bajo, M.A., Costero, O., et al., 2003. Risk factors for abdominal wall complications in peritoneal dialysis patients. Perit. Dial. Int., 23(3):249-254.

[5]Fick-Brosnahan, G.M., Belz, M.M., McFann, K.K., et al., 2002. Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: a longitudinal study. Am. J. Kidney Dis., 39(6):1127-1134.

[6]Fletcher, S., Turney, J.H., Brownjohn, A.M., 1994. Increased incidence of hydrothorax complicating peritoneal dialysis in patients with adult polycystic kidney disease. Nephrol. Dial. Transplant., 9(7):832-833.

[7]Grantham, J.J., Torres, V.E., Chapman, A.B., et al., 2006. Volume progression in polycystic kidney disease. N. Engl. J. Med., 354(20):2122-2130.

[8]Hadimeri, H., Johansson, A.C., Haraldsson, B., et al., 1998. CAPD in patients with autosomal dominant polycystic kidney disease. Perit. Dial. Int., 18(4):429-432.

[9]Janeiro, D., Portoles, J., Maria Tato, A., et al., 2015. Peritoneal dialysis can be an option for dominant polycystic kidney disease: an observational study. Perit. Dial. Int., 35(5):530-536.

[10]Kumar, S., Fan, S.L., Raftery, M.J., et al., 2008. Long term outcome of patients with autosomal dominant polycystic kidney diseases receiving peritoneal dialysis. Kidney Int., 74(7):946-951.

[11]Li, L., Szeto, C.C., Kwan, B.C., et al., 2011. Peritoneal dialysis as the first-line renal replacement therapy in patients with autosomal dominant polycystic kidney disease. Am. J. Kidney Dis., 57(6):903-907.

[12]Li, P.K., Szeto, C.C., Piraino, B., et al., 2010. Peritoneal dialysis-related infections recommendations: 2010 update. Perit. Dial. Int., 30(4):393-423.

[13]Liu, Z.H., 2013. Nephrology in China. Nat. Rev. Nephrol., 9(9):523-528.

[14]Lobbedez, T., Touam, M., Evans, D., et al., 2011. Peritoneal dialysis in polycystic kidney disease patients. Report from the French peritoneal dialysis registry (RDPLF). Nephrol. Dial. Transplant., 26(7):2332-2339.

[15]Pandya, B.K., Friede, T., Williams, J.D., 2004. A comparison of peritonitis in polycystic and non-polycystic patients on peritoneal dialysis. Perit. Dial. Int., 24(1):79-81.

[16]Spithoven, E.M., Kramer, A., Meijer, E., et al., 2014. Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival—an analysis of data from the ERA-EDTA Registry. Nephrol. Dial. Transplant., 29(Suppl. 4):iv15-iv25.

[17]Twardowski, Z.J., Nolph, K.D., Khanna, R., et al., 1987. Peritoneal equilibration test. Perit. Dial. Int., 7(3):138-147.

[18]Yu, X., Yang, X., 2015. Peritoneal dialysis in China: meeting the challenge of chronic kidney failure. Am. J. Kidney Dis., 65(1):147-151.